Allogeneic hematopoietic cell transplantation efficacy in patients with Philadelphia chromosome-positive acute myeloid leukemia in complete remission.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
19
02
2020
accepted:
22
07
2020
revised:
15
07
2020
pubmed:
2
8
2020
medline:
22
6
2021
entrez:
2
8
2020
Statut:
ppublish
Résumé
Philadelphia chromosome-positive acute myeloid leukemia (Ph+ AML) confers a dismal prognosis when treated with chemotherapy alone. Data on allogeneic hematopoietic cell transplantation (allo-HCT) outcomes are limited. We retrospectively analyzed 4649 AML patients who received allo-HCT and were in complete remission. Outcomes of Ph+ AML (n = 30), intermediate-risk, and poor-risk AML patients were compared. The 3-year overall survival after allo-HCT was similar in intermediate-risk (62.7%; 95% CI: 61.0-64.3%) and Ph+ AML (73.3%; 95% CI: 51.5-86.4%) groups (P = 0.42); however, it differed significantly between the poor-risk (49.7%; 95% CI: 45.9-53.4%) and Ph+ AML (73.3%; 95% CI: 51.5-86.4%) groups (P = 0.049). Disease-free survival in Ph+ AML patients was comparable to that in intermediate-risk patients but better than that in poor-risk patients. Relapse rates were significantly lower in Ph+ AML patients than in other groups. Non-relapse mortality (NRM) rates were similar among groups. Multivariate analysis showed that Ph+ AML was not a significant predictor of poor prognosis in terms of overall survival, disease-free survival, relapse, and NRM. Our data showed better post-transplant outcomes for Ph+ AML patients than for those with poor-risk AML. Hence, allo-HCT could be a feasible treatment option for Ph+ AML patients.
Identifiants
pubmed: 32737447
doi: 10.1038/s41409-020-01011-0
pii: 10.1038/s41409-020-01011-0
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
232-242Références
Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129:424–47. https://doi.org/10.1182/blood-2016-08-733196 .
doi: 10.1182/blood-2016-08-733196
pubmed: 27895058
pmcid: 27895058
Konoplev S, Yin CC, Kornblau SM, Kantarjian HM, Konopleva M, Andreeff M, et al. Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia. Leuk Lymphoma 2013;54:138–44. https://doi.org/10.3109/10428194.2012.701739 .
doi: 10.3109/10428194.2012.701739
pubmed: 22691121
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391–405. https://doi.org/10.1182/blood-2016-03-643544 .
doi: 10.1182/blood-2016-03-643544
Paietta E, Racevskis J, Bennett JM, Neuberg D, Cassileth PA, Rowe JM, et al. Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience. Leukemia 1998;12:1881–5. https://doi.org/10.1038/sj.leu.2401229 .
doi: 10.1038/sj.leu.2401229
pubmed: 9844918
Cuneo A, Ferrant A, Michaux JL, Demuynck H, Boogaerts M, Louwagie A, et al. Philadelphia chromosome-positive acute myeloid leukemia: cytoimmunologic and cytogenetic features. Haematologica 1996;81:423–7.
pubmed: 8952155
O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, et al. Acute myeloid leukemia, version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017;15:926–57. https://doi.org/10.6004/jnccn.2017.0116 .
doi: 10.6004/jnccn.2017.0116
pubmed: 28687581
Lazarevic VL, Labopin M, Depei W, Yakoub-Agha I, Huynh A, Ljungman P, et al. Relatively favorable outcome after allogeneic stem cell transplantation for BCR-ABL1-positive AML: A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT). Am J Hematol 2018;93:31–9. https://doi.org/10.1002/ajh.24928 .
doi: 10.1002/ajh.24928
pubmed: 28971504
Chantepie SP, Michallet M, Blaise D, Maury S, Deconinck E, Tabrizi R, et al. Allogeneic stem cell transplantation (allo-SCT) for de novo Ph+ AML: a study from the French Society of Bone Marrow Transplantation and Cell Therapy. Bone Marrow Transplant 2015;50:1586–8. https://doi.org/10.1038/bmt.2015.206 .
doi: 10.1038/bmt.2015.206
pubmed: 26367219
Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol 2007;86:269–74. https://doi.org/10.1532/ijh97.06239 .
doi: 10.1532/ijh97.06239
Atsuta Y. Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol 2016;103:3–10. https://doi.org/10.1007/s12185-015-1894-x .
doi: 10.1007/s12185-015-1894-x
Swerdlow SH. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for research on cancer; 2008.
Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A. et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9:1783–6.
pubmed: 7564526
Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991;28:250–9.
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825–8.
pubmed: 7581076
pmcid: 7581076
Giralt S, Logan B, Rizzo D, Zhang MJ, Ballen K, Emmanouilides C, et al. Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program. Biol Blood Marrow Transplant 2007;13:844–52. https://doi.org/10.1016/j.bbmt.2007.03.011 .
doi: 10.1016/j.bbmt.2007.03.011
pubmed: 17580263
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009;15:1628–33. https://doi.org/10.1016/j.bbmt.2009.07.004 .
doi: 10.1016/j.bbmt.2009.07.004
pubmed: 19896087
pmcid: 19896087
Yanada M, Mori J, Aoki J, Harada K, Mizuno S, Uchida N, et al. Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients. Leuk Lymphoma. 2018;59:601–9. https://doi.org/10.1080/10428194.2017.1357173 .
doi: 10.1080/10428194.2017.1357173
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013;48:452–8. https://doi.org/10.1038/bmt.2012.244 .
doi: 10.1038/bmt.2012.244
Soupir CP, Vergilio JA, Dal Cin P, Muzikansky A, Kantarjian H, Jones D, et al. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am J Clin Pathol 2007;127:642–50. https://doi.org/10.1309/B4NVER1AJJ84CTUU .
doi: 10.1309/B4NVER1AJJ84CTUU
pubmed: 17369142
Bhatt VR, Akhtari M, Bociek RG, Sanmann JN, Yuan J, Dave BJ, et al. Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute myeloid leukemia. J Natl Compr Canc Netw 2014;12:963–8. https://doi.org/10.6004/jnccn.2014.0092 .
doi: 10.6004/jnccn.2014.0092
pubmed: 24994916
Min GJ, Kim HJ, Yoon JH, Kwak DH, Park SS, Jeon YW, et al. Impact of an additional chromosome on the clinical outcomes of hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia in adults. Biol Blood Marrow Transplant 2018;24:1621–8. https://doi.org/10.1016/j.bbmt.2018.04.020 .
doi: 10.1016/j.bbmt.2018.04.020
pubmed: 29698793
Hahn T, McCarthy PL Jr, Zhang MJ, Wang D, Arora M, Frangoul H, et al. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol 2008;26:5728–34. https://doi.org/10.1200/jco.2008.17.6545 .
doi: 10.1200/jco.2008.17.6545
pubmed: 18981462
pmcid: 2645611
Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98:2043–51. https://doi.org/10.1182/blood.v98.7.2043 .
doi: 10.1182/blood.v98.7.2043
pubmed: 11567988
Eisner MD, August CS. Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation. Bone Marrow Transplant 1995;15:663–8.
pubmed: 7670393
Weisdorf D, Hakke R, Blazar B, Miller W, McGlave P, Ramsay N, et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 1991;51:1197–203. https://doi.org/10.1097/00007890-199106000-00010 .
doi: 10.1097/00007890-199106000-00010
pubmed: 2048196
Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007;110:4576–83. https://doi.org/10.1182/blood-2007-06-097386 .
doi: 10.1182/blood-2007-06-097386
pubmed: 17785583
pmcid: 17785583
Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ, et al. Marrow transplantation from related donors other than HLA-identical siblings. New Engl J Med 1985;313:765–71. https://doi.org/10.1056/nejm198509263131301 .
doi: 10.1056/nejm198509263131301
pubmed: 3897863
Anasetti C, Beatty PG, Storb R, Martin PJ, Mori M, Sanders JE, et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 1990;29:79–91. https://doi.org/10.1016/0198-8859(90)90071-v .
doi: 10.1016/0198-8859(90)90071-v
pubmed: 2249952
Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011;117:3214–9. https://doi.org/10.1182/blood-2010-08-302109 .
doi: 10.1182/blood-2010-08-302109
pubmed: 21263156
pmcid: 3062319
Nash RA, Pepe MS, Storb R, Longton G, Pettinger M, Anasetti C, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992;80:1838–45.
doi: 10.1182/blood.V80.7.1838.1838
Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen−a report from the acute leukemia working party of the European group for blood and marrow transplantation. J Clin Oncol 2013;31:3549–56. https://doi.org/10.1200/JCO.2013.48.8114 .
doi: 10.1200/JCO.2013.48.8114
pubmed: 23980086
Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood 2013;122:3863–70. https://doi.org/10.1182/blood-2013-07-514448 .
doi: 10.1182/blood-2013-07-514448
pubmed: 24065243
pmcid: 3854108
Huang B, Lin X, Zhang Z, Zhang Y, Zheng Z, Zhong C, et al. Comparison of tacrolimus and cyclosporine combined with methotrexate for graft versus host disease prophylaxis after allogeneic hematopoietic cell transplantation. Transplantation. 2020;104:428–36. https://doi.org/10.1097/tp.0000000000002836 .
doi: 10.1097/tp.0000000000002836
pubmed: 31283681
Nakasone H, Kawamura K, Yakushijin K, Shinohara A, Tanaka M, Ohashi K, et al. BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient. Blood Adv 2019;3:1750–60. https://doi.org/10.1182/bloodadvances.2019000077 .
doi: 10.1182/bloodadvances.2019000077
pubmed: 31182560
pmcid: 6560341
Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003;9:215–33. https://doi.org/10.1053/bbmt.2003.50026 .
doi: 10.1053/bbmt.2003.50026
pubmed: 12720215
Carlens S, Ringdén O, Remberger M, Lönnqvist B, Hägglund H, Klaesson S, et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant 1998;22:755–61. https://doi.org/10.1038/sj.bmt.1701423 .
doi: 10.1038/sj.bmt.1701423
pubmed: 9827972
Storb R, Prentice RL, Sullivan KM, Shulman HM, Deeg HJ, Doney KC, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med 1983;98:461–6. https://doi.org/10.7326/0003-4819-98-4-461 .
doi: 10.7326/0003-4819-98-4-461
pubmed: 6340576
Ozawa S, Nakaseko C, Nishimura M, Maruta A, Cho R, Ohwada C, et al. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program. Br J Haematol 2007;137:142–51. https://doi.org/10.1111/j.1365-2141.2007.06543.x .
doi: 10.1111/j.1365-2141.2007.06543.x
pubmed: 17391494
Neuendorff NR, Burmeister T, Dorken B, Westermann J. BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features. Ann Hematol 2016;95:1211–21. https://doi.org/10.1007/s00277-016-2721-z .
doi: 10.1007/s00277-016-2721-z
pubmed: 27297971
Reboursiere E, Chantepie S, Gac AC, Reman O. Rare but authentic Philadelphia-positive acute myeloblastic leukemia: two case reports and a literature review of characteristics, treatment and outcome. Hematol Oncol Stem Cell Ther 2015;8:28–33. https://doi.org/10.1016/j.hemonc.2014.09.002 .
doi: 10.1016/j.hemonc.2014.09.002
pubmed: 25300567